Health & Biotech
Opyl upbeat on early sales and growing customer database for AI- clinical trial recruitment platform
Health & Biotech
Creso Pharma’s Halucenex gets green light for Phase 2 clinical trial of psilocybin for PTSD
Health & Biotech
Incannex hits the Nasdaq for a wider audience
Health & Biotech
Global fashion industry watches as Nanollose completes first pilot spin of ground-breaking, eco-friendly Nullarbor-20™ lyocell fibre
Health & Biotech
Dr Boreham’s Crucible: A cure for the common cold? Why Firebrick Pharma might pass the sniff test
Health & Biotech
ScoPo’s Powerplays: Case of courage under fire for ASX health stocks
Health & Biotech
ASX Health Stocks: Results show revenue is growing in first half, but profitability still elusive
Health & Biotech
Cronos Australia just announced a 1100pc increase in revenue to ~$27.37 million in H1 FY22 and delivered a ~$3.37m net profit
Health & Biotech
Dimerix’s trading update confirms 2022 an exciting year as clinical development pathway advances
Health & Biotech
ASX Health Stocks: Here’s a highlight from today’s half-year result announcements
Health & Biotech
Singular enters giant East Asia medical VR market with breakthrough Macau JV
Health & Biotech
InteliCare doubles sales revenue as aged care AI delivers record customer growth
Featured Health & Biotech Stocks
Health & Biotech
Healthcare stocks are as varied as the solutions they are working to solve. The sector covers biotech stocks developing breakthrough pharmaceutical drugs and vaccines to medtech companies launching the latest and greatest medical devices they hope will change the face of healthcare.
Even the ‘budding’ medical cannabis industry is in the mix as researchers explore new applications and treatments.
If you want to know what’s happening with emerging health stocks on the ASX, Stockhead has you covered, with daily stock news, expert insight and research. You can also recap broader industry trends and recent share price movements across the sector in our regular ‘Check Up’ feature.
Accurate, up-to-date news stories are important, especially in the health sector where progress is often slow and risk often high. That’s why we’re focused on helping small cap investors make sense of the medical jargon.